Pharmacokinetics and Bio-distribution of New Gd-complexes of DTPA-bis (amide) (L3) in a Rat Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose : To investigate the blood pharmacokinetics and bio-distribution of DTPA-bis-amide (L3) Gd(III) complexes. Materials and Methods: The pharmacokinetics and bio-distribution of Gd (L3)(H2O).nH2O were investigated in Sprague-Dawley rats after intravenous administration at a dose of 0.1 mmol Gd/kg. The Gd content in the blood, various tissues,and organs was determined by ICP-AES. Blood pharmacokinetic parameters were calculated using a two-compartment model. Results: The half-lives of αphase and βphase Gd (L3)(H2O).nH2O were 2.286±0.11 min and 146.1±7.5min, respectively. The bio-distribution properties reveal that the complex is mainly excreted by the renal pathway, and possibly excreted by the hepatobiliary route. The concentration ratio of Gd (III) was significantly higher in the liver and spleen than in other organs, and small amounts of Gd (III) ion were detected in the blood or other tissues of rats only after 7 days of intravenous administration. Conclusion: The MRI contrast agent Gd (L3)(H2O).nH2O provides prolonged blood pool retention in the circulation and then clears rapidly with minimal accumulation of Gd(III) ions. The synthesis of gadolinium complexes with well-balanced lipophilicity and hydrophilicity shows promise for their further development as blood pool MRI contrast agents.
Abstract
Purpose : To investigate the blood pharmacokinetics and bio-distribution of DTPA-bis-amide (L3) Gd(III) complexes. Materials and Methods: The pharmacokinetics and bio-distribution of Gd (L3)(H2O).nH2O were investigated in Sprague-Dawley rats after intravenous administration at a dose of 0.1 mmol Gd/kg. The Gd content in the blood, various tissues,and organs was determined by ICP-AES. Blood pharmacokinetic parameters were calculated using a two-compartment model. Results: The half-lives of αphase and βphase Gd (L3)(H2O).nH2O were 2.286±0.11 min and 146.1±7.5min, respectively. The bio-distribution properties reveal that the complex is mainly excreted by the renal pathway, and possibly excreted by the hepatobiliary route. The concentration ratio of Gd (III) was significantly higher in the liver and spleen than in other organs, and small amounts of Gd (III) ion were detected in the blood or other tissues of rats only after 7 days of intravenous administration. Conclusion: The MRI contrast agent Gd (L3)(H2O).nH2O provides prolonged blood pool retention in the circulation and then clears rapidly with minimal accumulation of Gd(III) ions. The synthesis of gadolinium complexes with well-balanced lipophilicity and hydrophilicity shows promise for their further development as blood pool MRI contrast agents.
참고문헌 (19)
- Mansfield P, "Nmr imaging in biomedicine: Supplement 2 advances in magnetic resonance", Access Online via Elsevier, ~ (1982)
- Tzourio-Mazoyer N, "Automated anatomical labeling of activations in spm using a macroscopic anatomical parcellation of the MRI single-subject brain", Neuroimage, 15, pp.273~289 (2002)
- Ostergaard L, "High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part i: Mathematical approach and statistical analysis", Magn Reson Med, 36, pp.715~725 (1996)
- Tofts PS, "Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: standardized quantities and symbols", J Magn Reson Imaging, 10, pp.223~232 (1999)
- Caravan P, "Gadolinium (iii) chelates as MRI contrast agents: structure, dynamics, and applications", Chemical Reviews, 99, pp.2293~2352 (1999)
- Jacques V, "New classes of MRI contrast agents, In Contrast agents i", pp.123~164 (2002), Springer
- Aime S, "Gd (iii)-based contrast agents for MRI", Adv Inorg Chem, 57, pp.173~237 (2005)
- Tofts PS, "Modeling tracer kinetics in dynamic Gd-DTPA MR imaging", J Magn Reson Imaging, 7, pp.91~101 (1997)
- Hamm B, "Phase i clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging", Radiology, 195, pp.785~792 (1995)
- Kobayashi H, "Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores", Bioconjugate Chem, 14, pp.388~394 (2003)
- Caravan P, "Strategies for increasing the sensitivity of gadolinium based MRI contrast agents", Chem Soc Rev, 35, pp.512~523 (2006)
- Dutta S, "Gd-complexes of DTPA-bis (amide) conjugates of tranexamic acid and its esters with high relaxivity and stability for magnetic resonance imaging", Dalton Trans, 28, pp.2199~2206 (2008)
- Gu S, "Gdcomplexes of 1, 4, 7, 10-tetraazacyclododecane-n, n′, n′′, n′′′-1, 4, 7, 10-tetraacetic acid (DOTA) conjugates of tranexamates as a new class of blood-pool magnetic resonance imaging contrast agents", J Med Chem, 54, pp.143~152 (2010)
- Wedeking P, "Dissociation of gadolinium chelates in mice: relationship to chemical characteristics", Magn Reson Imaging, 10, pp.641~648 (1992)
- Parmelee DJ, "Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging", Invest Radiol, 32, pp.741~747 (1997)
- Zech CJ, "Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses gd-eob-dtpa (gadoxetic acid) with standard gddtpa", Invest Radiol, 44, pp.305~310 (2009)
- Fasano M, "The extraordinary ligand binding properties of human serum albumin", IUBMB life, 57, pp.787~796 (2005)
- Samiotaki G, "A quantitative pressure and microbubble-size dependence study of focused ultrasound-induced blood-brain barrier opening reversibility in vivo using mri", Magn Reson Med, 67, pp.769~777 (2012)
- Borlongan C, "Facilitation of drug entry into the cns via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, cereport", Brain Res Bull, 60, pp.297~306 (2003)